🇺🇸 FDA
Patent

US 10758614

Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 10758614 (Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase) held by THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH
Grant date
Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K31/337, A61K31/415